Sapere Bio, established in 2013 by Dr. Norman "Ned" Sharpless and Dr. Natalia Mitin, originated from groundbreaking research conducted in Dr. Sharpless' lab at the Lineberger Cancer Center, University of North Carolina, Chapel Hill.

Dr. Sharpless' lab was instrumental in uncovering mechanisms of aging and identifying the role of senescence in both aging and chronic diseases. Notably, their pivotal research highlighted the dual role of p16—a marker and regulator of senescence—in tumor suppression and aging.

Leveraging this foundational knowledge, Sapere Bio has developed innovative products based on immune aging biomarkers, including p16. Our mission is to revolutionize how aging is assessed and applied in clinical decision-making.

Dr. Sharpless, who has recently concluded his role as Director of the National Cancer Institute, now focuses on Sapere Bio alongside Dr. Mitin, who leads the company.